ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.
November 08, 2024 08:00 ET
|
Artidis AG
BASEL, Nov. 8, 2024 — ARTIDIS, a clinical-stage health technology company developing the first clinically integrated nanomechanical platform for tissue analytics, today announced a peer-reviewed...
Former U.S. CDC Director joins Board of Swiss health technology company: ARTIDIS announces board appointment of Dr. Julie Gerberding, President and CEO of the U.S. Foundation for the National Institutes of Health (FNIH)
September 24, 2024 09:00 ET
|
Artidis AG
BASEL, Sept. 24, 2024 — ARTIDIS today announced the appointment of Dr. Julie Louise Gerberding to its Board of Directors, effective immediately. Dr. Gerberding is President and CEO of the Foundation...
ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside
November 02, 2023 08:00 ET
|
Artidis AG
Houston, Texas, and Basel, Switzerland, November 2nd, 2023 – As Breast Cancer Awareness Month concludes, ARTIDIS announces the launch of its global multicenter clinical trial, ARTIDIS Nanomechanical...
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors
February 13, 2023 07:15 ET
|
Artidis AG
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors Basel, Switzerland, February 13, 2023 – ARTIDIS AG, a clinical stage medical technology company on a mission to shift...
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
October 03, 2022 09:05 ET
|
ARTIDIS AG
HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...
ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer
May 04, 2021 01:00 ET
|
Artidis AG
Basel, Switzerland, May 4, 2021 – ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the...
ARTIDIS investigates nanomechanical tissue signature to improve response to radio/immuno-therapy in lung cancer
December 21, 2020 07:30 ET
|
Artidis AG
Basel, Switzerland, December 21, 2020 – ARTIDIS AG, a privately held health-tech company, investigates the predictive value of nanomechanical tissue signature on outcomes in response to cancer...
ARTIDIS First Prospective Study, "NANO”, Evaluating its Nanotechnology Platform Based on a Novel Nanomechanical Biomarker in Breast Cancer Meets Primary Endpoint
June 22, 2020 07:42 ET
|
Artidis AG
Basel, Switzerland, June 22, 2020 - ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in...